DSNTV: FlavoRx’s Baker on integrating flavoring, its role in building relationships
At this year’s National Association of Chain Drug Stores Total Store Expo, Drug Store News was walking the show floor talking to vendors about their potential as partners to retailers. In the first installment of four videos from NACDS TSE, DSN talks to FlavoRx SVP marketing Chad Baker about how the company helps pharmacies make medication more palatable for children and makes it easy for pharmacists to flavor medication by integrating it into existing reconstitution workflow. He also discusses the impact on the patient-pharmacist relationship that takes place as a result of the interaction that FlavoRx spurs.
“For pharmacies, now more than ever, they’re focused on that customer experience and really making sure that when customers come through the door they feel like they’re engaged with their pharmacist and a great relationship with the pharmacy team,” Baker said. “That’s what everyone talks about; that’s what we do — we provide a reason for these pharmacies to engage with their customers.”
Smith Drug adds associate VP strategic accounts
SPARTANBURG, S.C. — Smith Drug has a new addition to its staff. The company named Joe Willaman to the newly created position of associate VP strategic accounts. In the position, Willaman will work with regional chains to highlight the benefits of Smith Drug’s products and services.
“Joe joined our team two years ago and has made a significant impact on our business,” Smith Drug and Burlington Drug president Jeff Foreman said. “Joe’s experience in Strategic Programs are a natural fit for this market segment. He was integral in developing our pricing optimization program, which is a tremendous benefit for all of our customers.”
Willaman, a graduate of Ohio University, has previously worked in marketing at Cardinal Health and in generics, pricing and national accounts at McKesson.
“I am looking forward to the opportunity to lead this growth initiative,” Willaman said. “Smith Drug and Burlington Drug are known for the excellent service and support it gives to all of its customers, and I intend to see that our regional chain customers receive that same level of attention.”
FDA approves new formulation of Pfizer’s Lyrica
SILVER SPRING, Md. — Pfizer’s Lyrica has an approved new formulation. The Food and Drug Administration on Thursday approved Lyrica CR (pregabalin) controlled-release tablets.
The tablets are indicated as a once-daily treatment for neuropathic pain associated with diabetic peripheral neuropathy and to manage postherpetic neuralgia. It was not approved for fibromyalgia management.
“Lyrica CR was developed to offer patients an effective treatment option with the convenience of once-daily dosing,” Pfizer Global Product Development chief development officer for internal medicine Dr. James Rusnak said. “It provides an important option for patients and health care providers managing these often debilitating pain conditions.”